Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1529731
Reference Type
Journal Article
Subtype
Review
Title
Endogenous Nitric Oxide Synthase Inhibitors in the Biology of Disease Markers, Mediators, and Regulators?
Author(s)
Caplin, Ben; Leiper, J
Year
2012
Is Peer Reviewed?
1
Journal
Arteriosclerosis, Thrombosis, and Vascular Biology
ISSN:
1079-5642
EISSN:
1524-4636
Volume
32
Issue
6
Page Numbers
1343-+
Language
English
PMID
22460557
DOI
10.1161/ATVBAHA.112.247726
Web of Science Id
WOS:000304428400006
Abstract
The asymmetric methylarginines inhibit nitric oxide synthesis in vivo by competing with L-arginine at the active site of nitric oxide synthase. High circulating levels of asymmetric dimethylarginine predict adverse outcomes, specifically vascular events but there is now increasing experimental and epidemiological evidence that these molecules, and the enzymes that regulate this pathway, play a mechanistic role in cardiovascular diseases. Recent data have provided insight into the impact of altered levels of these amino acids in both humans and rodents, however these reports also suggest a simplistic approach based on measuring, and modulating circulating asymmetric dimethylarginine alone is inadequate. This review outlines the basic biochemistry and physiology of endogenous methylarginines, examines both the experimental and observational evidence for a role in disease pathogenesis, and examines the potential for therapeutic regulation of these molecules.
Keywords
kidney; nitric oxide; nitric oxide synthase; vascular biology; asymmetric dimethylarginine
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity